SaudiVax, a leading biopharmaceutical company in Saudi Arabia, Minapharm Pharmaceuticals, a premier biopharmaceutical company and global provider of proprietary technologies headquartered in Egypt with multiple subsidiaries in Berlin, and MiGenTra GmbH , a healthcare transforming medicines company headquartered in Berlin, today announced the signing on 26th September 2023 of a Memorandum of Understanding (MoU) for the companies to jointly pursue potential business opportunities in Saudi Arabia and the Gulf Cooperation Countries (Region).
The partnership is intended to leverage the companies’ strengths, matching Minapharm’s and MiGenTra’s cutting-edge development and manufacturing technologies and translational experience of high-quality affordable bio-engineered products with SaudiVax’s industrial capabilities and commercial reach in the Region.
This landmark MOU marks a significant step towards ensuring national health security and achieving biomanufacturing autonomy in Saudi Arabia, ultimately contributing to the overall healthcare ecosystem. Together, the Parties are committed to advancing healthcare solutions and meeting the growing demand for high-quality biologics in the Region.
